[
    {
        "gene": "NAT2",
        "rank": 1,
        "explanation": "NAT2 acetylates P-aminosalicylic acid in the human liver. Acetylation of the drug leads to urinary excretion. NAT2 fast metabolizers excrete the drug more rapidly and therefore need higher doses. On the other hand, NAT2 slow metabolizers have elevated plasma levels and may experience increased toxicity. Therefore, NAT2 pharmacogenetic testing can personalize the treatment with P-aminosalicylic acid, lowering the risk of side effects and ensuring the expected therapeutic effect."
    },
    {
        "gene": "NAT1",
        "rank": 2,
        "explanation": "The enzyme encoded by NAT1 also acetylates P-aminosalicylic acid. However, this action occurs mainly in extrahepatic tissues. NAT1 fast metabolizers might excrete the drug more rapidly in these tissues, reducing its local action. Slow metabolizers may have an extended action but may be at risk of local toxicity. Therefore, despite occurring in a different compartment, the role of NAT1 in P-aminosalicylic acid pharmacogenetics is very significant."
    },
    {
        "gene": "ABCB1",
        "rank": 3,
        "explanation": "ABCB1 codes for P-glycoprotein, one of the main efflux transporters in the human body. P-glycoprotein is expressed predominantly in the liver, kidneys and intestines, and it promotes the excretion of a wide variety of drugs and toxins, including P-aminosalicylic acid. Therefore, variations in the ABCB1 gene that diminish the function of P-glycoprotein could lead to elevated plasma levels and increased toxicity of P-aminosalicylic acid. Conversely, ABCB1 fast metabolizers may require a higher dosage of the drug to achieve the desired therapeutic effect."
    },
    {
        "gene": "CYP2C9",
        "rank": 4,
        "explanation": "CYP2C9 polymorphisms significantly influence the metabolism of various medications, thereby impacting their therapeutic effects and risk of side effects. Although the influence of CYP2C9 on p-aminosalicylic acid is not well established, the possibility of metabolic interaction exists based on the enzyme's extensive role in the biotransformation of other drugs, necessitating further exploration."
    },
    {
        "gene": "CYP2C19",
        "rank": 5,
        "explanation": "CYP2C19 plays a major role in affecting the metabolism of various drugs such as clopidogrel, proton pump inhibitors like omeprazole and esomeprazole, antidepressants like citalopram, escitalopram, antiepileptics like phenytoin, antifungals like voriconazole, and analgesics like methadone and oxycodone. Its variants have been found to significantly impact drug activation and metabolism, leading to differing pharmacological outcomes across individuals."
    },
    {
        "gene": "ABCC2",
        "rank": 6,
        "explanation": "ABCC2 codes for the multidrug resistance-associated protein 2 (MRP2), an efflux transporter expressed primarily in the liver and kidneys. MRP2 contributes to the biliary and urinary excretion of various drugs and toxins. P-aminosalicylic acid could be a substrate of MRP2. Therefore, ABCC2 genetic variations can influence the clearance of P-aminosalicylic acid, with potential clinical implications on drug plasma concentrations, efficacy, and side effects."
    },
    {
        "gene": "CYP2C8",
        "rank": 7,
        "explanation": "CYP2C8 is known for playing a critical role in the metabolism of drugs like paclitaxel, pioglitazone, repaglinide, and amodiaquine. Genetic variations that influence drug metabolism and exposure directly impact the efficacy and toxicity profiles of these drugs, suggesting the potential utility of CYP2C8 genetic testing in optimizing drug dosing and reducing toxicity risks."
    },
    {
        "gene": "CYP2E1",
        "rank": 8,
        "explanation": "CYP2E1 is involved in the metabolism of several drugs, leading to differences in their effectiveness, toxicity, and corresponding adverse effects. The gene may impact p-aminosalicylic acid's metabolism in a similar manner, possibly affecting its pharmacokinetics and clinical response."
    },
    {
        "gene": "SLC22A1",
        "rank": 9,
        "explanation": "SLC22A1 encodes the organic cation transporter 1 (OCT1). OCT1 is expressed mainly in the liver, where it facilitates the cellular uptake of various drugs. P-aminosalicylic acid is a cation at physiological pH and can be a substrate of OCT1. Therefore, genetic variants that modify the activity of the transporter can influence the hepatic clearance of the drug, altering its plasma levels and possibly its therapeutic effect and toxicity."
    },
    {
        "gene": "CYP2D6",
        "rank": 10,
        "explanation": "CYP2D6 plays a significant role in drug metabolism, particularly in the metabolism of drugs like codeine, antidepressants like paroxetine and fluoxetine, the antipsychotic risperidone, tamoxifen, and beta-blockers such as metoprolol and timolol. The variations in CYP2D6 activity can result in different therapeutic responses and outcomes, with poor metabolizers at risk of the potential toxicity and ultra-rapid metabolizers at risk of reduced drug efficacy."
    }
]